Browse our complete catalog of research peptides
$199.99
Retatrutide (LY3437943) is a novel triple agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 clinical trial data published in the New England Journal of Medicine showed significant metabolic effects. ≥99% purity, COA included.
Retatrutide (LY3437943) is a novel triple agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 clinical trial data published in the New England Journal of Medicine showed significant metabolic effects. ≥99% purity, COA included.
Hey there 👋
Claim 20% OFF your first order with code "PEPTIDE20" at checkout.
We're here to help with any questions about our products, orders, or support.
Reviews
There are no reviews yet.